Damora Therapeutics, Inc.

Damora Therapeutics, Inc. is a biopharmaceutical company that develops therapies for hematologic disorders in Denmark and North America. Its lead product is DMR-001, an investigational monoclonal antibody therapy targeting CALR mutations for the treatment of essential thrombocythemia. The company also develops DMR-002 and DMR-003, both anti-mutCALR-based therapies intended to ultimately address the full spectrum of mutCALR MPN patients, as well as GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.